Welcome to the e-CCO Library!

P586: A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Plevris N., Deekae A., Jones G.R., Manship T.A., Noble C.L., Satsangi J., Shand A.G., Arnott I.D., Lees C.W.

Created: Wednesday, 20 February 2019, 10:36 AM
P586: Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn’s disease: a multi-centre retrospective cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Townsend*1, V. Razanskaite2, S. Michail1, J. Morgan1, M. Davies1, D. Storey1, C. Watters3, D. Penman3, M. Swaminathan4, J. Sabine3, A. Chapman2, A. Vyas2, I. Reilly4, P. Flanagan3, K. Bodger2, S. Subramanian1

Created: Friday, 22 February 2019, 9:41 AM
P586: Drug-induced lipid changes in patients with Inflammatory Bowel Disease: a single center, prospective study
Year: 2021
Source: ECCO'21 Virtual
Authors: SleutjesAM, J.(1);de Vries, A.C.(1);Roeters van Lennep, J.E.(2);van der Woude, C.J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P586: Surgical recurrence in Crohn’s Disease: Can we prevent it?
Year: 2022
Source: ECCO'22
Authors: Botto, I.(1);Serrazina, J.(1);Coelho Rodrigues, I.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P586: Tofacitinib for the induction and maintenance of medically resistant ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Weisshof*, M. Aharoni Golan, D.T. Rubin

Created: Thursday, 21 February 2019, 9:14 AM
P586: Vedolizumab in Mild to Moderate Crohn's Disease Patients Naïve to Biological Therapy: a Multicentric Observational Study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dotti, A.Z.(1);Vilela, E.G.(2);Chebli, J.M.F.(3);Chebli, L.A.(4);Magro, D.O.(5);Steinwurz, F.(6);Argollo, M.(7);Carvalho, N.S.(7);Parente, J.M.L.(8);Parra, R.S.(9);Perin, R.L.(10);Flores, C.(11);Morsoletto, E.M.(12);Ferreira, S.D.C.(13);Ludvig, J.C.(14);Kaiser Jr, R.L.(15);Queiroz, N.S.F.(16);Faria, M.A.G.(17);Nicollelli, G.M.(18);Andrade, A.R.(19);KotzeMD- PhD, P.G.(20)*;
Created: Friday, 14 July 2023, 11:05 AM
P587 Adalimumab in pediatric Crohn’s disease: A long-term multi-centre real-world experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Lawrence1, H. Huynh2, W. El-Matary3, J. DeBruyn4, M. Carroll2, E. Wine2, J. Chan1, K. Jacobson1

Created: Thursday, 30 January 2020, 10:12 AM
P587: Disease severity in the INFLAMMATORY BOWEL DISEASES: Do patients and physicians agree?
Year: 2022
Source: ECCO'22
Authors: Timmer, A.(1);de Sordi, D.(1);Neuser, J.(1);Seibel, K.(1);Hensel, A.(1);Schmidt-Lauber, M.(2);Allgayer, H.(3);Klebl, F.(4);Obermeier, F.(4);Jessen, P.(5);Schnoy, E.(6);Helwig, U.(7);Morgenstern, J.(8);Leifeld, L.(9);Schmidt, S.(9);Meinhardt, C.(10);Maaser, C.(11);Bästlein, E.(12);Bokemeyer, A.(13);Graefe, U.(14);Kühbacher, T.(15);Kaltz, B.(16);Sander, C.(16);Wolfgang, K.(17);
Created: Friday, 11 February 2022, 3:56 PM
P587: Drug survival of vedolizumab-treated inflammatory bowel disease patients in a nationwide observational cohort study: ICC case series
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Biemans1,2*, C. van der Woude3, G. Dijkstra4, A. van der Meulen - de Jong5, B. Oldenburg6, N. de Boer7, C. Ponsioen8, A. de Vries3, J. Haans2, M. Pierik2, F. Hoentjen9, Dutch Initiative on Crohn and Colitis (ICC)

Created: Thursday, 21 February 2019, 9:14 AM
P587: Fermentation capacity of gut microbiota in patients with inflammatory bowel disease compared to healthy controls
Year: 2017
Source: ECCO '17 Barcelona
Authors:

McGowan M.1, Kokkorou M.2, Rebull M.1, Koh Y.3, Gaya D.R.4, Hansen R.5, Russell R.K.5, Gerasimidis K.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P587: Intestinal ultrasound (IUS) and magnetic resonance imaging (MRI) for monitoring of response to therapy in luminal Crohn's disease – a systematic review.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Lovett, G.(1,2)*;Schulberg, J.D.(1,2);Hamilton, A.L.(1,2);Wilding, H.E.(3);Kamm, M.A.(1,2);Wright, E.K.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P587: Quality of care indicators in inflammatory bowel disease: local pilot study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Sarraj*1, F. Bravo1, M. Maude1, A. Macpherson1, P. Juillerat1

Created: Friday, 22 February 2019, 9:41 AM
P587: Utility of intestinal ultrasound in Inflammatory Bowel Disease patients on management decisions
Year: 2021
Source: ECCO'21 Virtual
Authors: Abraham, B.(1);Saleh, A.(2);Perry, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P588 vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Marino1, R. Domenis2, L. Biribin1, A. Cifù2, L. Navarria1, G. Scardino1, M. Fabris2

Created: Thursday, 30 January 2020, 10:12 AM
P588: Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jairath, V.(1,2,3)*;Zou, G.(2,3,4);Wang, Z.(3);Adsul, S.(5);Colombel, J.F.(6);D'Haens, G.R.(7);Freire, M.(5);Moran, G.W.(8,9);Peyrin-Biroulet, L.(10);Sandborn, W.J.(11);Sebastian, S.(12,13);Travis, S.(14);Vermeire , S.(15);Radulescu, G.(3);Sigler, J.(3);Mcfarlane, S.(3);Arya, N.(16);Beaton, M.(1);Bossuyt, P.(17);Green, D.(18);Harlan III, W.(19);Horynski, M.(20);Klopocka, M.(21,22);Petroniene, R.(23);Silverberg, M.S.(24);Wolanski, L.(25);Feagan , B.G.(1,2,3);
Created: Friday, 14 July 2023, 11:05 AM
P588: Steroid sparing effect of adalimumab in cortisone–depended ulcerative colitis patients
Year: 2021
Source: ECCO'21 Virtual
Authors: SinaDr., M.(1);Pengili, E.(1);Pemaj, X.(1);Osmanaj, D.(1);Bibolli, I.(1);Prifti, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P588: Switching from infliximab originator to a first biosimilar is safe and effective: A single-centre series with through levels and anti-drug antibodies determination
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Daperno*, C. Guiotto, A. Italia, A. Lavagna, A. Negri, E. Ercole, M. Cosimato, C. Rigazio, R. Rocca

Created: Thursday, 21 February 2019, 9:14 AM
P588: T cell response to SARS-CoV-2 mRNA vaccines by an interferon-gamma release immunoassay in patients with Inflammatory Bowel disease receiving anti-TNF and thiopurine treatment
Year: 2022
Source: ECCO'22
Authors: Mayorga Ayala, L.F.(1);Herrera-deGuise, C.(1);Esperalba, J.(2);Martinez-Gomez, X.(6);Céspedes Martinez, E.(1);Robles Alonso, V.(1);Jimenez, A.(1);Perez Martinez, Z.(1);Oller, E.(1);Ibarz, A.(1);Fernandez-Naval, C.(3);Martinez-Gallo, M.(4);Lopez Messeguer, M.(5);Casellas, F.(1);Borruel, N.(1);
Created: Friday, 11 February 2022, 3:56 PM
P588: Tacrolimus suppositories: a safe and effective treatment for treatment-refractory proctitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Smith*1, H. Weekes2, L. Morgan2, M. Parkes1, J. C. Lee1

Created: Friday, 22 February 2019, 9:41 AM
P588: Ustekinumab for the treatment of Crohn's disease patients with TNF antagonist induced psoriasis. Real life experience from a tertiary referral center through week 54
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kuehbacher T.*1, Abu Hashem R.1, Langel N.1, Schreiber S.2, Drvarov O.1

Created: Wednesday, 20 February 2019, 10:36 AM